| |
Research |
|
Development |
|
Market |
| ANTI-INFECTIVE |
| ENDG0010 Sinus Infections
|
 |
| ENDG0020 Ear Infections
|
|
| ENDG1010 Pneumonia |
|
| ENDG1020 Meningitis |
|
| ENDG1030 Cystic Fibrosis |
|
| ENDG1040 MRSA |
|
| ENDG1050 Mixed Bacterial |
|
| HEAD TRAUMA |
| ENDG2010 CNS Inflammation, Endothelin based formulation |
|
| ENDG2020 CNS Inflammation, Mannitol modification
|
|
| ANALGESICS |
| ENDG3010 Non-opiate Analgesic
|
|
| ENDG3020 Opiate Analgesic |
|
| ONCOLOGY |
| ENDG4010 Tumor Imaging |
|
| ENDG4020 Solid tumor treatment
(Out licensed phase I) |
 |
| STROKE |
| ENDG5010 Stroke blood flow |
|
| ENDG5020 Hypothermia
|
|
| DEMENTIA AND ALZHEIMER'S DISEASE |
| ENDG6010 Prevention/treatment |
|
| OPIATE TOLERANCE/ADDICTION |
| ENDG7010 Eliminate tolerance
|
|
| ENDG7020 Use in withdrawal
|
|
| EPILEPSY |
| ENDG8010 Prevention/treatment |
|
|
